Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Unicycive Therapeutics, Inc.

Ticker
UNCY
Sector
Industry
Report date
November 17, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Unicycive’s ongoing regulatory progress with the FDA acceptance of the oxylanthanum carbonate NDA resubmission and the company’s third quarter 2026 financial results. The stock experienced a notable decline in October 2026, with analysis suggesting potential for trend reversal. The company resubmitted the NDA with new manufacturing data in late 2026, and the FDA accepted this resubmission, initiating another review cycle.

Recent developments:
  • Unicycive Therapeutics announced FDA acceptance of the oxylanthanum carbonate NDA resubmission and reported third quarter 2026 financial results [N1].
  • The company’s stock lost 21.4% over four weeks in October 2026, with commentary discussing possible trend reversal [N2].
  • Unicycive resubmitted the oxylanthanum carbonate NDA to the FDA with new manufacturing data in September 2026 [N3].
  • In July 2026, Unicycive was noted as disappointing in a weekly biotech update despite other companies gaining FDA nods [N4].
  • Unicycive participated in a fireside chat at Guggenheim’s Emerging Outlook: Biotech Summit in February 2026 [N5].
  • The FDA accepted the NDA resubmission for oxylanthanum carbonate in January 2026, setting a PDUFA date of June 29, 2026 [N6][N7][N8].
Overview

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company established in 2016, focused on developing innovative therapies for kidney diseases, particularly chronic kidney disease (CKD) and acute kidney injury (AKI). The company’s business model centers on licensing drug candidates and advancing them through clinical development and regulatory approval, initially targeting the U.S. market with plans for global partnerships. Its pipeline includes oxylanthanum carbonate (OLC), a next-generation phosphate binder designed to improve treatment adherence by reducing pill burden and enhancing palatability, and UNI-494, a novel candidate for AKI treatment. OLC’s NDA was submitted in 2024, accepted by the FDA, but received a Complete Response Letter in 2025 due to manufacturing deficiencies at a third-party vendor. The company addressed these issues and resubmitted the NDA, which was accepted again in 2026. Clinical trials have demonstrated tolerability and phosphate control in dialysis patients. Financially, as of September 30, 2026, Unicycive reported $41.97 million in cash and equivalents and a net loss of $7.0 million for the quarter ending that date.

Executive summary

Unicycive Therapeutics, Inc. is a clinical-stage biotech company focused on kidney disease therapies, primarily developing oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients and UNI-494 for acute kidney injury. The company operates by licensing drug candidates and advancing them through clinical trials toward FDA approval. OLC's NDA was initially accepted in 2024 with a PDUFA date in 2025 but received a Complete Response Letter due to manufacturing issues. After addressing these, the NDA was resubmitted and accepted again in 2026, with ongoing FDA review. Financially, as of September 30, 2026, Unicycive held $41.97 million in cash and equivalents and reported a net loss of $7.0 million for the quarter. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for UNCY

Bull case model:

Unicycive’s oxylanthanum carbonate leverages novel nanoparticle technology to potentially improve phosphate binder therapy by reducing pill burden and enhancing palatability, addressing a large unmet need in CKD patients on dialysis. The company has demonstrated clinical tolerability and phosphate control in Phase 2 trials. The FDA has accepted multiple NDA submissions, indicating regulatory progress. The company’s focused approach on kidney disease and efficient development platform may facilitate advancement of its pipeline and partnerships for commercialization.

Bear case model:

The company’s lead product candidate, oxylanthanum carbonate, has faced regulatory setbacks including a Complete Response Letter due to manufacturing deficiencies, which could delay approval. As a clinical-stage biotech, Unicycive has yet to generate significant revenue and reported net losses. The success of its pipeline depends on regulatory approvals and market acceptance. Risks include potential disruptions from strategic transactions, manufacturing challenges, and competition from existing phosphate binders. Financial resources and execution risks remain significant factors.

Moat:

Unicycive’s moat derives from its proprietary nanoparticle technology for oxylanthanum carbonate, which aims to address significant unmet needs in hyperphosphatemia treatment by offering higher potency with fewer and smaller pills, potentially improving patient adherence. The company’s focused expertise in kidney disease, combined with a streamlined drug development platform and strategic licensing model, supports efficient advancement of its pipeline. Its management team’s industry experience and network may provide advantages in identifying and acquiring promising assets. However, as a clinical-stage biotech, the moat is contingent on successful regulatory approvals and commercialization.

Risks overview
Risks summary
The most significant risk is regulatory uncertainty related to manufacturing compliance and FDA approval processes, which directly affect the company’s ability to commercialize its lead product.
Risks details:

• Regulatory Risk: The FDA issued a Complete Response Letter for oxylanthanum carbonate due to manufacturing deficiencies at a third-party vendor, requiring resubmission and review delays.
• Financial Risk: The company reported net losses and relies on capital to fund operations; insufficient funding or unfavorable financing terms could impact development.
• Strategic Transaction Risk: Future acquisitions or partnerships may disrupt business, dilute stockholders, or fail to strengthen competitive position, as disclosed in the latest 10-Q.
• Clinical and Commercial Risk: Success depends on clinical trial outcomes, regulatory approvals, and market acceptance of novel therapies in a competitive landscape.

FINAL FORECAST FOR UNCY

Final take one line
Unicycive Therapeutics has very high visibility due to detailed SEC disclosures and extensive recent news on its kidney disease drug development and regulatory progress.
Final take 12 to 24 month view

Business trends: Continued focus on kidney disease therapies with regulatory review of oxylanthanum carbonate NDA and clinical development of UNI-494.
Execution milestones: FDA NDA resubmissions and acceptance, clinical trial completions, and addressing manufacturing compliance issues.
Key risks: Regulatory approval uncertainty, manufacturing compliance, financial sustainability, and strategic transaction impacts.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease, specifically chronic kidney disease (CKD) and acute kidney injury (AKI).
  • Founded in 2016, the company operates by licensing drug candidates and developing them through clinical trials toward regulatory approval and commercialization, initially targeting the U.S. market with plans to partner globally.
  • The company’s pipeline includes two main product candidates: oxylanthanum carbonate (OLC), a next-generation phosphate binder for hyperphosphatemia in CKD patients on dialysis, and UNI-494, a novel drug candidate for acute kidney injury.
  • Oxylanthanum carbonate leverages proprietary nanoparticle technology to deliver higher phosphate binding potency with fewer and smaller pills, aiming to improve patient adherence compared to existing phosphate binders.
  • The company submitted an NDA for OLC to the FDA in September 2024, which was accepted with a PDUFA action date initially set for June 28, 2025.
  • The FDA issued a Complete Response Letter (CRL) in June 2025 due to manufacturing deficiencies at a third-party vendor; no clinical or safety concerns were identified.
  • Unicycive held a Type A meeting with the FDA in October 2025 to address the manufacturing issues and resubmitted the NDA in December 2025.
  • The FDA accepted the NDA resubmission in January 2026, classifying it as a Class II complete response with a six-month review period and a new PDUFA date of June 29, 2026.
  • The company resubmitted the NDA again with new manufacturing data, and the FDA accepted this resubmission in November 2026, initiating another review cycle.
  • Clinical trials include a Phase 2 pivotal study in dialysis patients showing tolerability and phosphate control, with 90% of patients achieving target serum phosphate levels after washout of prior binders.
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $41.97 million, short-term investments of $17.01 million, current assets of $69.16 million, and current liabilities of $17.31 million, resulting in a current ratio of 4.0 and a cash ratio of 3.41.
  • The company reported a net loss of $7.0 million and basic and diluted EPS of -$0.25 for the quarter ended September 30, 2026.
  • Unicycive’s business model focuses on addressing significant unmet medical needs in kidney disease through innovative therapies with potential clinical and economic benefits.
  • The company faces risks related to strategic transactions that could disrupt business or dilute stockholders, as disclosed in the latest 10-Q filing.
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-17 | www.nasdaq.com | Unicycive Therapeutics Announces FDA Acceptance of OLC NDA Resubmission and Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/unicycive-therapeutics-announces-fda-acceptance-olc-nda-resubmission-and-third-quarter
  • N2 | 2026-10-13 | www.nasdaq.com | Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner | https://www.nasdaq.com/articles/unicycive-therapeutics-uncy-loses-214-4-weeks-heres-why-trend-reversal-may-be-around
  • N3 | 2026-09-29 | www.nasdaq.com | Unicycive Therapeutics Resubmits Oxylanthanum Carbonate NDA To FDA | https://www.nasdaq.com/articles/unicycive-therapeutics-resubmits-oxylanthanum-carbonate-nda-fda
  • N4 | 2026-07-02 | www.nasdaq.com | Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal | https://www.nasdaq.com/articles/weekly-buzz-vrtx-aptx-gain-fda-nod-uncy-disappoints-ipsen-opens-wallet-vtgn-misses-goal
  • N5 | 2026-02-04 | www.globenewswire.com | Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit | https://globenewswire.com/news-release/2026/02/04/3231919/0/en/Unicycive-Therapeutics-to-Participate-in-a-Fireside-Chat-at-Guggenheim-s-Emerging-Outlook-Biotech-Summit.html
  • N6 | 2026-01-29 | www.globenewswire.com | UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission | https://www.globenewswire.com/news-release/2026/01/29/3228698/0/en/UPDATE-Unicycive-Therapeutics-Announces-FDA-Acceptance-of-Oxylanthanum-Carbonate-OLC-New-Drug-Application-NDA-Resubmission.html
  • N7 | 2026-01-29 | www.nasdaq.com | Unicycive Therapeutics Announces FDA Acceptance For Resubmitted Oxylanthanum Carbonate NDA | https://www.nasdaq.com/articles/unicycive-therapeutics-announces-fda-acceptance-resubmitted-oxylanthanum-carbonate-nda
  • N8 | 2026-01-29 | www.globenewswire.com | Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission | https://www.globenewswire.com/news-release/2026/01/29/3228435/0/en/Unicycive-Therapeutics-Announces-FDA-Acceptance-of-Oxylanthanum-Carbonate-OLC-New-Drug-Application-NDA-Resubmission.html
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine